

The University of Manchester



Choon SE^{1,2}, Wright AK³, Griffiths CEM^{4,5}, Tey KE^{1,2}, Wong KW^{1,2}, Lee YW¹, Suvelayutnan U⁶, Mariapun J², Ashcroft DM^{3,4}, on behalf of the Global Psoriasis Atlas

¹Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Malaysia ²Jeffrey Cheah School of Medicine & Health Sciences, Monash University, Malaysia ³Division of Pharmacy and Optometry, University of Manchester ⁴NIHR Manchester Biomedical Research Centre, University of Manchester ⁵Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester ⁶Department of Information and Communication Technology, Hospital Sultanah Aminah Johor Bahru

Introduction

- Around 60 million people worldwide have psoriasis; however, the GPA identified that 81% of countries in the world lack information on the epidemiology of psoriasis.
- The prevalence of psoriasis varies greatly among different geographical populations; in adults it ranges from 0.14% in East Asia to $\sim 2\%$ in Australasia and Europe.
- However, there is no population-based epidemiological data on psoriasis in Southeast Asia, including Malaysia.

The aim of this study was to estimate, for the first time, the annual incidence and prevalence of psoriasis over an 11-year period in multi-ethnic Malaysians in the Johor Bahru district, and determine if there was variation in rates by sex, age and ethnicity.

Methods

- We used routinely collected electronic health records from the Teleprimary Care (TPC) clinical information system, a locally developed database linking public primary and secondary care facilities.
- Psoriasis was identified by ICD-10 diagnostic codes, with all diagnoses validated by dermatologists. The index date was defined as the first recorded diagnosis of psoriasis regardless of phenotype or where the diagnosis was first documented.
- The study population (denominator) comprised any patient who contributed ≥ 1 day in the TPC. Prevalent psoriasis cases were those with a diagnosis prior to the end of the year of interest. Incident psoriasis cases were patients with first presentation of psoriasis in the year of interest.
- The person-time at risk was calculated from the start of the each calendar year of interest or the day of registration until the index date, death, or end of the calendar year, whichever came first.
- Annual prevalence and incidence were estimated and stratified by age, sex, and ethnicity.
- Prevalence reported as a percentage and incidence per 100,000 person-years (py).
- The distribution of age of psoriasis onset was examined by plotting psoriasis incidence against age.



www.globalpsoriasisatlas.org

Incidence and prevalence of psoriasis in Malaysia between 2010 and 2020





Ð

ILDS







Global Psoriasis Atlas

Results

 Between 1st January 2010 and 31st December 2020, 1.16 million people in Johor Bahru were registered in TPC (~98% of the estimated population), with 3,932 with dermatologist-confirmed psoriasis.

The period prevalence rate of psoriasis was 0.34%; 0.39% in males, 0.29% in females

0.29% in Malays, 0.38% in Chinese, 0.54% in Indians

Prevalence rates increased steadily between 2010 and 2020 from 0.27% to 0.51%, Fig 1.

Prevalence consistently higher in males than females and highest amongst Indians, followed by Chinese and

Period incidence of psoriasis was 34.2/100,000 py;

40.7 in males, 28.3 in females 30.0 in Malays, 38.0 in Chinese, 52.5 in Indians

Incidence increased from 27.8/100,000py in 2010 to 60.9/100,000py in 2020, Fig 2.

Increasing trend in incidence observed across sex and ethnic groups with consistently higher rates in males

Modest bimodality in age of psoriasis onset observed in females and Malays with peaks at ages 20-29 & 50-59

 Mean age of psoriasis onset was 39.8±17.4 years; 42.0±17.2 years in males, 36.8±17.3 years in females 36.4±17.5 years in Malays, 47.4±16.9 years in Chinese,

40.8±15.2 years in Indians

Discussion

This study provides information for the first time on the burden of psoriasis in Southeast Asia.

Psoriasis incidence and prevalence are increasing and vary by age, sex and ethnicity.

 These findings should help inform healthcare planning, resource allocation and management of patients with psoriasis in Malaysia.

	A	R	
LEO FOUNDATION			
rie AM	GEN [®]	Lilly	U NOVARTIS
almirall feel the science	Janssen	PHARMACEUTICAL COMPANIES OF Johnnon-Johnnon	s
l Psoriasis Atlas has been supported by: The LEO Foundation, Abbvie, en, Janssen, Eli Lilly and Company, Novartis Pharma AG and UCB (2021/22)			

Our open access paper is available in the BJD

